Surgery for oligometastatic prostate cancer: Where are we going?

Actas Urol Esp (Engl Ed)

Departamento de Urología, Luzerner Kantonsspital, Luzern, Switzerland.

Published: September 2021

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acuroe.2021.06.006DOI Listing

Publication Analysis

Top Keywords

surgery oligometastatic
4
oligometastatic prostate
4
prostate cancer
4
cancer going?
4
surgery
1
prostate
1
cancer
1
going?
1

Similar Publications

Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma.

J Gastrointest Cancer

January 2025

Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Multiple randomized trials have suggested that the addition of comprehensive metastasis-directed therapy to best systemic therapy improves disease control and survival among patients with oligometastatic disease, even for histologies with a high propensity for rapid spread. Here, we review the growing literature supporting the oligometastatic paradigm in pancreatic ductal adenocarcinoma. We summarize key details from nascent institutional series and reflect on the recently reported phase II randomized EXTEND trial.

View Article and Find Full Text PDF

Is there a role for neoadjuvant therapies followed by radical cystectomy in oligometastatic bladder cancer?

Curr Opin Urol

January 2025

Department of Urology, Comprehensive Cancer Center Medical University Vienna, Vienna General Hospital, Vienna, Austria.

Purpose Of Review: This review explores the potential role of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) for oligometastatic bladder cancer (OMBC) treatment. We focused on extrapolating evidence from studies including lymph node-positive only and metastatic bladder cancer to address the key challenges and therapeutic strategies for OMBC.

Recent Findings: Current evidence for NAC and RC in OMBC is limited, with most data derived from studies in locally advanced bladder cancer.

View Article and Find Full Text PDF

Chapter 8: MANAGEMENT OF AGGRESSIVE FORMS OF PRIMARY HPT: PARATHYROID CARCINOMA AND ATYPICAL PARATHYROID TUMOR.

Ann Endocrinol (Paris)

January 2025

Imaging Department, Nuclear Medicine Service, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

Parathyroid carcinoma is extremely rare, affecting 1% of cases of primary hyperparathyroidism. For this reason, management is poorly codified and requires expertise in specialized center. PC is genetically determined in a quarter to a third of cases, notably involving the CDC73 gene coding for parafibromin.

View Article and Find Full Text PDF

The contemporary concept of carcinogenesis summarizes the role of hypoxia, neoangiogenesis, and hemostasis, including in the stage of progression and metastasis of the tumor process. Metastatic disease is a serious therapeutic challenge for any oncological condition. The purpose of this study was to evaluate the dynamics of specific indicators of neoangiogenesis and hypoxia as potential biomarkers for therapeutic efficacy or risk of disease progression in patients with brain metastases (BM) undergoing robotic stereotactic radiosurgery.

View Article and Find Full Text PDF

Background: The use of local consolidative therapy (LCT) in patients with oligometastatic non-small cell lung cancer (NSCLC) is rapidly evolving, with a preponderance of data supporting the benefits of such therapeutic approaches incorporating pulmonary resection for appropriately selected candidates. However, practices vary widely institutionally and regionally, and evidence-based guidelines are lacking.

Methods: The Society of Thoracic Surgeons assembled a panel of thoracic surgical oncologists to evaluate and synthesize the available evidence regarding the role of pulmonary resection as LCT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!